Hope for Epilepsy Patients, But Treatment Gap Exists Worldwide
An exciting discovery may change the way epilepsy is treated, but if current evidence is any indication, getting the treatment to patients will be a challenge.
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
FDA Approves Treatment for Rare Swelling Disease
Biopharmaceutical company Dyax Corporation has received regulatory approval to market its drug ecallantide (Kalbitor) for a rare genetic disorder called hereditary angioedema (HAE).
Provectus Reports Positive Preliminary Data for Dermatology Drug
Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.
Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
[Company Profile] Ivivi Technologies
This targeted, a priori designed, micro-current is designed to enhance and accelerate the body’s natural healing processes to help repair injured tissue and to reduce related pain and inflammation.
Join Us at the 3rd Annual OneMedPlace Finance Forum
Over 100 companies and 500 investors are expected to attend the OneMedPlace Finance Forum, to take place from January 12-14 in San Francisco.
CytRx to Initiate Clinical Trial for Soft Tissue Cancer Drug
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.